Caninized PD-1 monoclonal antibody in oral malignant melanoma: efficacy and exploratory biomarker analysis

20260 citationsJournal Articlegold Open Access

Authors

Masaya Igase · Yamaguchi University

Kenji HAGIMORI · Kyoto Medical Center

Sakuya Inanaga · Yamaguchi University

Hiroki Mizoguchi · Kyoto College of Medical Science

Kazuhito ITAMOTO · Yamaguchi University

Masashi Sakurai · Yamaguchi University

Tomoki Motegi ·

Abstract

ca-4F12-E6 exhibited durable antitumor activity with manageable safety profile in dogs with OMM. Baseline systemic inflammatory markers and MSI status may serve as predictive biomarkers for clinical outcomes. The results support the use of canine OMM as a comparative model for human immuno-oncology and biomarker discovery.

Topics & Keywords

Veterinary Oncology Research Cutaneous Melanoma Detection and Management Cancer Immunotherapy and Biomarkers

Publication Details

Published in: Journal for ImmunoTherapy of Cancer

Volume 14, Issue 1, pp. e013623-e013623

DOI: 10.1136/jitc-2025-013623

Field-Weighted Citation Impact: 0.00

Command Palette

Caninized PD-1 monoclonal antibody in oral malignant melanoma: efficacy and exploratory biomarker analysis

Authors

Abstract

Topics & Keywords

Publication Details